Nexavar starts Phase III adjuvant trial in liver cancer
This article was originally published in Scrip
Bayerand Onyx have commenced a Phase III trial evaluating their multi-targeted anticancer Nexavar (sorafenib) as an adjuvant treatment in hepatocellular carcinoma (HCC), or primary liver cancer. The US FDAhas completed a special protocol assessment (SPA) for the STORM (Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma) trial, which is expected to enrol about 1,100 patients who had their tumours removed. The study will be conducted at more than 200 sites in North America, South America, Europe and the Asia-Pacific region.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.